People
Crucial Data Solutions, a provider of innovative technologies to advance clinical research, announced that industry veteran Jeff Rogers has joined the company as President.
Long Crendon, Buckinghamshire, UK, 6th August 2019 – Softbox, a leading global innovator and provider of temperature control packaging and thermal covers for the life science and logistics industries, has announced the appointment of Kevin Valentine as Softbox’s new global CEO, effective 1st September 2019.
Company strengthens board ahead of trial results in type 1 diabetes patients and expansion of indications for its proprietary Imotope™ technology
Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics.
Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.
Pharma and biotech companies from across the globe expand their leadership teams and boards.
Matthew J. Bair, M.D., M.S., a research scientist with the Regenstrief Institute and the U.S. Department of Veterans Affairs, will co-lead a $21 million national study to find the best approach to manage chronic low back pain.
Great Bay Bio, a leading biotechnology company dedicated to innovative biologics CMC (Chemistry Manufacturing and Controls) and development of biologics development big data platform, the board is pleased to announce the introduction of a new non-executive director, Mr. William Kung.
Cristal Therapeutics announces that Dr Werner Cautreels is joining the Company’s supervisory board taking on the role of Chairman.
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
PRESS RELEASES